A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
SecuraBio
Study ID
NCT07714187
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cutaneous T-cell Lymphoma
  • Mycosis Fungoides

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Duvelisib — DRUG
    Topical gel

Study Details

This study will evaluate the safety and preliminary efficacy of duvelisib topical gel in participants with early-stage mycosis fungoides.

Key Dates

First listed
Jul 20, 2026
Start date
Jan 31, 2027
Status verified
Jul 2026
Primary completion
Oct 31, 2028
Completion
Jan 31, 2029

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Duvelisib

Primary Outcome Measure

Number of Participants with Treatment-emergent Adverse Events (TEAEs) [ Time Frame: Baseline through Day 114 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Johns Hopkins UniversityBaltimoreMaryland21218-

Find similar trials in Baltimore, MD

By research site
Johns Hopkins University· Baltimore, MD

Related Studies